Fungal Infections Complicating COVID-19

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread globally to pandemic proportions. Although the majority of cases have asymptomatic or mild infections, a significant proportion of cases progress to severe pneumonia and acute resp...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2021
Language:English
Physical Description:1 electronic resource (98 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03226nam-a2200841z--4500
001 993545671404498
005 20231214133546.0
006 m o d
007 cr|mn|---annan
008 202201s2021 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000041887 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/76280 
035 |a (EXLCZ)995400000000041887 
041 0 |a eng 
100 1 |a Hoenigl, Martin  |4 edt 
245 1 0 |a Fungal Infections Complicating COVID-19 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2021 
300 |a 1 electronic resource (98 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread globally to pandemic proportions. Although the majority of cases have asymptomatic or mild infections, a significant proportion of cases progress to severe pneumonia and acute respiratory distress syndrome requiring critical care. Opportunistic infections following severe respiratory viral infections have been recognized since the 1918 influenza pandemic. Among critically ill patients with COVID-19, secondary fungal infections caused by Aspergillus and Candida spp. are increasingly described, affecting up to 30% of COVID-19 patients requiring intensive care treatment. This collection of manuscripts focuses on fungal infections complicating COVID-19, including immunological mechanisms and pathogenesis, diagnosis, and treatment. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a SARS-CoV-2 
653 |a co-infection 
653 |a pulmonary aspergillosis 
653 |a ICU 
653 |a azole-resistant Aspergillus 
653 |a Aspergillus fumigatus 
653 |a CAPA 
653 |a TR34L98H 
653 |a SARS COV-2 
653 |a Aspergillus 
653 |a novel coronavirus 
653 |a superinfection 
653 |a risk factors 
653 |a prevalence 
653 |a challenges 
653 |a immune response 
653 |a expert statement 
653 |a European Confederation of Medical Mycology 
653 |a COVID-19 
653 |a fungaemia 
653 |a Saccharomyces 
653 |a co-infections 
653 |a invasive aspergillosis 
653 |a putative 
653 |a probable 
653 |a Sars-CoV-2 
653 |a PCR 
653 |a galactomannan 
653 |a classification 
653 |a COVID-19 pneumonia 
653 |a invasive pulmonary aspergillosis 
653 |a diagnosis 
653 |a multi-triazole resistance 
653 |a COVID-19 associated invasive pulmonary aspergillosis 
653 |a coinfection 
653 |a diabetes 
653 |a bloodstream infection 
653 |a Candida glabrata 
653 |a echinocandin resistance 
653 |a FKS mutation 
653 |a candidemia 
653 |a candiduria 
653 |a oral candidiasis 
653 |a mycobiome 
776 |z 3-0365-0554-7 
776 |z 3-0365-0555-5 
700 1 |a Talento, Alida Fe  |4 edt 
700 1 |a Hoenigl, Martin  |4 oth 
700 1 |a Talento, Alida Fe  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:57:38 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337993950004498&Force_direct=true  |Z 5337993950004498  |b Available  |8 5337993950004498